BIOMATERIAL SUPPLIER LIABILITY WOULD BE LIMITED
This article was originally published in The Gray Sheet
Executive Summary
BIOMATERIAL SUPPLIER LIABILITY WOULD BE LIMITED under draft legislation released May 20 at a Senate Government Affairs/Regulation and Government Information Subcommittee hearing. Under the proposal, sponsored by subcommittee chairman Sen. Joseph Liebermann (D-Conn.), suppliers of "raw materials" or "component parts" for implants would be liable to civil action only if a claimant's "proximate cause of harm" was that materials did not meet specifications that were agreed upon by the manufacturer and supplier.